# TocilizuMab discontinuAtion in GIant Cell Arteritis

> **NCT06037460** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Centre Hospitalier Universitaire Dijon** · enrollment: 120 (actual)

## Conditions studied

- Giant Cell Arteritis

## Interventions

- **DRUG:** Tocilizumab treatment
- **OTHER:** questionnaires
- **BIOLOGICAL:** Blood samples
- **PROCEDURE:** 18FDG PET scan

## Key facts

- **NCT ID:** NCT06037460
- **Lead sponsor:** Centre Hospitalier Universitaire Dijon
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-05-13
- **Primary completion:** 2027-12
- **Final completion:** 2028-11
- **Target enrollment:** 120 (ACTUAL)
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06037460

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06037460, "TocilizuMab discontinuAtion in GIant Cell Arteritis". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT06037460. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*